TITLE:
Amelioration of Albuminuria in Japanese Type 2 Diabetic Patients by Maximal Dose of Candesartan
AUTHORS:
Yoichi Oikawa, Akira Shimada, Mizumi Kyo
KEYWORDS:
Albuminuria; Angiotensin II Receptor Blocker (ARB); Candesartan; Hypertension; Type 2 Diabetes
JOURNAL NAME:
Open Journal of Endocrine and Metabolic Diseases,
Vol.3 No.5,
September
20,
2013
ABSTRACT: Introduction: It was recently reported that candesartan, an
angiotensin II receptor blocker, had a protective effect against cardiovascular
events, comparable to that of calcium channel antagonists. Moreover, a
renoprotective effect and anti-diabetic action of candesartan had also been
demonstrated. However, whether the renoprotective effect of candesartan, especially
in diabetes, was dose-dependent or not remain to be fully elucidated. The
present study attempted to clarify the dose effect of renoprotection by
candesartan in Japanese type 2 diabetic patients. Subjects and Method: In this case series study, we recruited 26 type 2 diabetic patients with albuminuria whose
blood pressure did not reach the target BP level ( were increased
to the maximal dose in Japan, 12 mg/day. Clinical
parameters were examined before, at 6 and 12 months after the increase in dose. Results: An ameliorating effect of
the increased dose of candesartan on albuminuria and hypertension was
distinctly observed. No severe adverse effect was observed. Conclusion: It was highly possible that
the maximal dose of candesartan provided more effective renoprotection in
hypertensive type 2 diabetic patients initially treated with lower doses of
candesartan.